August 6, 2020 – The U.S. FDA has approved BlenrepTM (belantamab mafodotin-blmf), manufactured by
GlaxoSmithKline, for use as a single agent to treat adults who have
August 6, 2020 – The U.S. FDA has approved an expanded indication for Dovato® (dolutegravir/
lamivudine) oral tablets, manufactured by ViiV Healthcare. The drug is
August 3, 2020 – The U.S. FDA has approved Monjuvi® (tafasitamab-cxix), manufactured by MorphoSys
AG and Incyte, for use in combination with lenalidomide to treat adults
August 3, 2020 – The U.S. FDA has approved a new indication for Spravato® (esketamine) nasal spray,
manufactured by Janssen Pharmaceuticals. Spravato is now indicated for
July 30, 2020 – The U.S. FDA has approved a new indication for Tecentriq® (atezolizumab), manufactured
by Genetech. Tecentriq is now indicated for use with Genetech’s Cotellic®
July 30, 2020 – The U.S. FDA has approved an expanded indication for Stelara® (ustekinumab), manufactured by Janssen Pharmaceuticals. The drug is now indicated to
July 27, 2020 – The U.S. FDA has approved XeglyzeTM (abametapir 0.74% lotion), manufactured by Dr.
Reddy’s Laboratories, as a topical treatment for head lice infestation in
July 27, 2020 – The U.S. FDA has approved Amneal Pharmaceuticals’ generic version of Demser®
(metyrosine – Valeant Pharmaceutical) oral capsules. Metyrosine is indicated